TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15366325
Drug: Deramciclane 60
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 60 mg b.i.d. for 4 weeks
Study: 11535548
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day raloxifene
Study: 11451623
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day raloxifene
Study: 11451623
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate)
Study: 8052956
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.625 mg
Study: 8052956
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) 50 micrograms/24h
Study: 30078280
Drug: Hydromorphone (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.01 mg/kg)
Study: 27082036
Drug: Multi-component influenza
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component influenza and Tdap vaccine promotion package
Study: 14675952
Drug: Surgical access
Normalized name: ACCESS PIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical access therapy
Study: 14675952
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of metronidazole as an adjunct to mechanical treatment
Study: 14675952
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment
Study: 10527711
Drug: 7 ml
Normalized name: ethanol 7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 ml liquid cartilage extract
Study: 10527711
Drug: 21 ml
Normalized name: ethanol 0.21 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 ml liquid cartilage extract
Study: 1677063
Drug: Cyclosporin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (5 mg/kg per day)
Study: 6223289
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 200 micrograms fenoterol hydrobromide and 80 micrograms ipratropium bromide
Study: 26787637
Drug: Manually Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually Controlled Infusion (MCI)
Study: 24817188
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of continuous and intermittent theta-burst stimulation (Group C)
Study: 23010558
Drug: AZD6370 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6370 20 mg
Study: 23010558
Drug: AZD6370 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6370 60 mg
Study: 23010558
Drug: AZD6370 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6370 180 mg
Study: 23010558
Drug: AZD6370 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6370 (180 mg total dose in one, two or four divided doses)
Study: 19281330
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 15 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Study: 19281330
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Study: 19281330
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine (14 days apart)
Study: 10450538
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dihydroartemisinin
Study: 10450538
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dihydroartemisinin with 750 mg mefloquine
Study: 7761739
Drug: Caffeine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2 mg/kg) added to decaffeinated coffee at 2220 and 0120 hours for the first 3 nights.
Study: 2143266
Drug: Loratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (5 mg daily; 2.5 mg for children under 20 kg)
Study: 2143266
Drug: Dexchlorpheniramine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine (1 mg every 8 hours; 0.5 mg for the youngest children)
Study: 2143266
Drug: Overall clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall clinical assessment for both drugs
Study: 31999300
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg intravitreous injections)
Study: 31999300
Drug: Ranibizumab (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (after censoring VF results after PRP treatments)
Study: 31999300
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (initial PRP session)
Study: 31999300
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (additional PRP sessions)
Study: 31999300
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (endolaser)
Study: 30172451
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg daily for 12 weeks
Study: 30172451
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg daily for 4 weeks + 50 mg daily for 8 weeks
Study: 30172451
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg for 4 weeks followed by 50 mg for 8 weeks
Study: 18466654
Drug: Low GI
Normalized name: Yellow Ginger Root
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low GI and low GL (L-L)
Study: 18466654
Drug: High GI
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High GI and low GL (H-L)
Study: 10998876
Drug: PCEA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA using a disposable PCA device (3.0 ml type)
Study: 10998876
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural group with epidural fentanyl (15 micrograms.ml‐1) and bupivacaine (1.25 mg.ml‐1)
Study: 8698952
Drug: 8-session cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session cognitive-behavioral therapy (CB)
Study: 8698952
Drug: 16-session cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-session cognitive-behavioral therapy (CB)
Study: 8698952
Drug: 8-session psychodynamic-interpersonal
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session psychodynamic-interpersonal therapy (PI)
Study: 8698952
Drug: 16-session psychodynamic-interpersonal
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-session psychodynamic-interpersonal therapy (PI)
Study: 8698952
Drug: psychodynamic-interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: psychodynamic-interpersonal therapy (PI)
Study: 8698952
Drug: cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive-behavioral therapy (CB)
Study: 8698952
Drug: 8-session treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session treatments
Study: 8698952
Drug: 16-session treatments
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-session treatments
Study: 22155435
Drug: Beta-blocker (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (BB) up-titration
Study: 20422396
Drug: Antidepressant medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant medicines (ADMs) use
Study: 16940738
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 mug
Study: 15491319
Drug: Control protocol:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control protocol: rinsed twice daily for 1 min with 0.1% chlorhexidine (CHX) for 4 weeks.
Study: 15491319
Drug: Test protocol:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test protocol: applied CHX locally using a very soft surgical toothbrush from days 3 to 14, and a soft toothbrush from days 14 to 28, twice daily, in addition to CHX rinsing.
Study: 14655831
Drug: Citalopram at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram at a starting dose of 20 mg for 6 months
Study: 8306595
Drug: Self-titrating insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-titrating insulin regimen
Study: 8306595
Drug: Pre-mixed insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-mixed insulin (30:70) delivered by disposable pen
Study: 8306595
Drug: Insulin ratios
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin ratios other than 30:70
Study: 8306595
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for disposable pen and pre-mixed insulin regimen
Study: 30589994
Drug: ACT-774312 50
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-774312 50 mg twice daily
Study: 30589994
Drug: ACT-774312 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-774312 (single doses of 1-1000 mg or multiple doses of 30-500 mg)
Study: 29522079
Drug: Treatment-as-prevention intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-prevention intervention including monthly testing for HIV and rapid treatment initiation for those who became HIV-positive.
Study: 29522079
Drug: Monthly testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly testing for HIV among HIV-negative individuals.
Study: 26794930
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg/day)
Study: 26794930
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day; 6-week cycles of 4 weeks on, 2 weeks off)
Study: 24178792
Drug: Anatabine (9-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatabine (9-24 mg/d), administered orally 3 times a day for 3 months
Study: 24178792
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally 3 times a day for 3 months
Study: 17487260
Drug: Carvedilol in
Normalized name: Product containing carvedilol in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol in addition to ACE inhibitor
Study: 17487260
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor without any beta-blocker (control)
Study: 9654256
Drug: Interferon alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2a (3x10(6) IU, three times weekly for 18 months)
Study: 8270984
Drug: 20-mg tamoxifen
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg tamoxifen tablet taken once daily
Study: 8270984
Drug: 10-mg tamoxifen
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg tamoxifen tablet taken twice daily
Study: 2521930
Drug: Secondary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary prevention program including physical and behavioral therapy
Study: 28030526
Drug: JE chimeric
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE chimeric virus vaccine (JE-CV)
Study: 21868794
Drug: NSAIDs, physiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs, physiotherapy, and local steroid injection (group 2B)
Study: 15239872
Drug: Elective change
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective change of intravenous cannulae every 48 hours
Study: 11122017
Drug: Liarozole 50
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liarozole 50 mg
Study: 11122017
Drug: Liarozole 75
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liarozole 75 mg
Study: 11122017
Drug: Liarozole 150
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liarozole 150 mg
Study: 9124990
Drug: Piperacillin/tazobactam (P/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (P/T) administered as dropwise intravenous infusions in a single dose of 4/0.5 g 3 times a day for 5 to 17 days
Study: 8249561
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tetracaine diluted in 1 ml of 10% glucose
Study: 8249561
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tetracaine diluted in 2 ml of 10% glucose
Study: 8249561
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tetracaine diluted in 4 ml of 10% glucose
Study: 3524172
Drug: Moricizine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine therapy (10 mg/kg/day)
Study: 3524172
Drug: Moricizine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine therapy
Study: 29802630
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with keratinized mucosa (Group 1)
Study: 29802630
Drug: Implants without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants without keratinized mucosa (Group 2)
Study: 27203434
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg, monthly intravitreal injections for one year)
Study: 27203434
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg, monthly intravitreal injections for one year)
Study: 18541933
Drug: DOTS (thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS (thrice weekly for 2 months, followed by isoniazid and rifampicin thrice weekly for 4 months)
Study: 18541933
Drug: Daily tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tuberculosis chemotherapy (daily for 2 months, followed by isoniazid and rifampicin daily for 7 months)
Study: 18541933
Drug: Daily tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tuberculosis chemotherapy
Study: 10235547
Drug: Nilvadipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (4 mg/d) orally in NTG patients
Study: 10235547
Drug: Control (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (vehicle solution) in rabbits
Study: 8907805
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg daily for 12 weeks
Study: 8907805
Drug: Captopril 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 37.5 mg daily for 12 weeks
Study: 1905384
Drug: Quantitative methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative methods to measure drug usage
Study: 6342563
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (IPT), consisting of weekly individual psychotherapy for six months
Study: 6342563
Drug: Low-contact treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-contact treatment, consisting of one brief meeting per month for six months
Study: 15346948
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with polycomponent vaccine VP-4 (4 or 5 subcutaneous injections at an interval of 5-7 days)
Study: 15346948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving basic therapy
Study: 12190996
Drug: Miglitol 100
Normalized name: miglitol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 100 mg three times a day for 2 days (six doses total)
Study: 9807740
Drug: Allogeneic cell
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic cell therapy (AlloCT) with human recombinant interleukin 2 (rIL-2) for 3 days to activate donor PBL, followed by infusion of in vitro rIL-2 activated donor lymphocytes combined with 3-day rIL-2 therapy.
Study: 9807740
Drug: Allogeneic cell
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic cell therapy (AlloCT) with donor marrow cell infusion without further conditioning.
Study: 7622801
Drug: Mirtazapine (24‐72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (24‐72 mg/day)
Study: 7622801
Drug: Trazodone (150‐450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (150‐450 mg/day)
Study: 9663810
Drug: Selegiline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 10 mg
Study: 320476
Drug: Granulocyte transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte transfusion in addition to antibiotics
Study: 320476
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received appropriate antibiotic regimen alone
Study: 6753860
Drug: Ciprofibrate 50
Normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate 50 mg/day
Study: 6753860
Drug: Ciprofibrate 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate 100 mg/day
Study: 30554519
Drug: Monthly injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly injectable PrEP
Study: 25152283
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral transversus abdominis plane block with 0.25% ropivacaine 60 ml (group A)
Study: 22246200
Drug: 5-Fluorouracil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil (50 mg/ml)
Study: 18206039
Drug: Alprazolam (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.4 mg qd at 10PM for 3 days, n = 72)
Study: 15234399
Drug: Pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with clopidogrel for three days
Study: 15234399
Drug: Standard post-procedural
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard post-procedural treatment (Control)
Study: 11383794
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 300 mg bolus followed by 1.5 mg.kg(‐1).h(‐1) continuous infusion for 2 days
Study: 8364942
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ketorolac tromethamine
Study: 8364942
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hydrocodone plus 1000 mg of acetaminophen
Study: 28746076
Drug: Neublastin 50
Normalized name: NEUBLASTIN
DrugBank: Artemin (DB15438)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neublastin 50 μg/kg
Study: 28746076
Drug: Neublastin 1200
Normalized name: NEUBLASTIN
DrugBank: Artemin (DB15438)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neublastin 1200 μg/kg
Study: 28746076
Drug: All neublastin
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All neublastin doses
Study: 26135333
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray during follicular phase (F)
Study: 26135333
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray during luteal phase (L)
Study: 25713924
Drug: Video capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video capsule endoscopy (VCE) using the PillCam SB capsule endoscopy system
Study: 22811030
Drug: Sodium nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitrate supplementation (10 mg·kg of body mass)
Study: 17503683
Drug: Provider responses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provider responses to computer alerts regarding guideline recommendations for antihypertensive treatment.
Study: 11349696
Drug: 5 mg/dose
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/dose
Study: 11349696
Drug: 10 mg/dose
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/dose
Study: 11349696
Drug: 15 mg/dose
Normalized name: Valtoco, 15 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/dose
Study: 9484545
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cisapride during fasting
Study: 9484545
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cisapride followed 30 minutes later by ingestion of 300 mL of milk
Study: 9484545
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet during fasting
Study: 9484545
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet followed 30 minutes later by ingestion of 300 mL of milk
Study: 7869731
Drug: Benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 20 mg plus Hydrochlorothiazide 25 mg (BN + HCT)
Study: 7869731
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg plus Hydrochlorothiazide 25 mg (CP + HCT)
Study: 22882673
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol therapy (50 to 200 mg/day)
Study: 22882673
Drug: Rescue analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesia (topical cream with 3.33% doxepin and 0.05% capsaicin)